ARA-290 (Cibinetide): Receptor Biology, Human Studies, and Evidence Limits

Reviewed for accuracy by the Gorilla Research Insights research team · 2026-07-04

PEPTIDE RESEARCH SERIES ARA-290 (Cibinetide): Receptor Biology, Human Studies, and Evidence Limits ARA-290, also called cibinetide, is an investigational 11-amino-acid peptide derived from erythropoietin. The useful scientific question is not whether it is a general “repair peptide,” but whether selective signaling proposed for this molecule produces reproducible effects in defined experimental systems.

What researchers are studying

ARA-290 was designed to retain tissue-protective signaling associated with erythropoietin while minimizing classical erythropoietic activity. The “innate repair receptor” model is a mechanistic hypothesis supported by experimental work, not a license to infer whole-body repair from receptor terminology. A 22-participant randomized pilot study in sarcoidosis-associated small-fiber-neuropathy symptoms reported improvement on one symptom instrument, while pain and fatigue changes did not differ from placebo ^[1]. A later phase 2 study in type 2 diabetes and painful neuropathy reported exploratory metabolic, symptom, and corneal-nerve findings; subgroup analyses and the study’s scale limit generalization ^[2].

What the evidence does—and does not—establish

These studies show that cibinetide has reached controlled human investigation. They do not establish efficacy for unrelated inflammatory conditions, injury recovery, organ protection, or consumer use. Small samples, multiple outcomes, selected populations, and short observation periods increase uncertainty. Findings for an investigational clinical formulation also do not establish identity, purity, sterility, or biological equivalence of any separately supplied research material. Published trial tolerability observations are specific to those protocols and populations. They cannot establish broad safety, long-term risk, interactions, or safety outside supervised research.

Better research questions

• Which receptor complex and downstream signals are necessary for observed effects? • Are nerve-structure findings replicated prospectively with prespecified endpoints? • Which results persist in larger, independently conducted trials?

Primary sources

• ^[1] Heij L, et al. Randomized, double-blind pilot study in sarcoidosis-associated small-fiber-neuropathy symptoms. PubMed . • ^[2] Brines M, et al. Phase 2 investigation in type 2 diabetes and painful neuropathy. PubMed . Educational research summary only; not medical advice or instructions for use.